Digitization – Key Topic of our Time
September at Chromicent was all about digitalization. In cooperation with the HTW Berlin, we have subjected Chromicent to a digital checkup as part of the… Read More »Digitization – Key Topic of our Time
News
EMA – Statement Nitrosamine
The EMA has published a final statement on nitrosamine impurities in medicinal products. The full report can be found *here*. The publication of Chromicent is… Read More »EMA – Statement Nitrosamine
News from the Chromicent
Dear customers and friends of Chromicent, we have good news and would like to share it with you. You will find our detailed information letter… Read More »News from the Chromicent
New: Size Exclusion Chromatography (SEC)
Chromicent has enhanced its portfolio with size exchange chromatography (SEC). This chromatographic method enables us to separate molecules in solution by size (hydrodynamic volume) and… Read More »New: Size Exclusion Chromatography (SEC)
ICH Q2/Q14 Analytical Procedure Life Cycle Management
This conference provides a comprehensive overview of the new ICH Quality Guideline Q14 on Analytical Procedure Development, and the revised Q2 Guideline on Validation of… Read More »ICH Q2/Q14 Analytical Procedure Life Cycle Management
Analytical Design Space Modeling
We are pleased to recommend another webinar: Analytical design space modeling in accordance with ICH Q12 and proposed Q14: Using a novel approach for in… Read More »Analytical Design Space Modeling
Challenge: Nitrosamines
In the field of pharmaceutical safety, nitrosamines remain a crucial issue. In a webinar entitled “Analysis of nitrosamines in APIs by LC/MS: How to face… Read More »Challenge: Nitrosamines
Method LifeCycle Management from Chromicent GmbH speeds up drug development considerably. Contribution of the Berlin-based company to coping with the “Corona crisis”
Events such as the coronavirus pandemic make us aware that access to innovative, affordable and safe medicines is one of the challenges of our time… Read More »Method LifeCycle Management from Chromicent GmbH speeds up drug development considerably. Contribution of the Berlin-based company to coping with the “Corona crisis”
The current situation
Dear customers and friends of Chromicent, the Chromicent, like all of us, faces great challenges. Our SOP “Pandemic Plan” was activated at the beginning of… Read More »The current situation
Nitrosamine
In accordance with Article 31 of Directive 2001/83/EC, the EMEA expects all pharmaceutical manufacturers to provide information on nitrosamines contained in medicinal drugs by the… Read More »Nitrosamine